Borden Cottage, a private recovery retreat in Camden, has appointed Jeff Jay as its new President and CEO.

Jay is a clinician, author, and interventionist with decades of experience in addiction and mental health recovery, according to a news release issued July 30. Borden Cottage serves individuals seeking help with substance use and co‑occurring mental health disorders.

"His leadership represents the next step in Borden Cottage’s ongoing evolution as a center of excellence for personalized, world‑class care," according to the release. 

“Jeff Jay’s reputation in the field is unparalleled,” said Tom Rodman, founder of Borden Cottage, in the release. “He has spent his career at the forefront of clinical innovation and compassionate family intervention. I look forward to working closely with Jeff as we build on the strong foundation we’ve established and continue setting the standard for private, individualized recovery.”

"Our work is grounded in compassion, clinical excellence, and a deep belief in each person’s ability to change," said Jo-Ann Cook, Borden Cottage Clinical Director. "Jeff Jay’s leadership is a natural fit. His integrity, decades of experience, and unwavering commitment to family-centered care make him an ideal steward of our mission."

Jay's book, Love First: A Family’s Guide to Intervention in Addiction and Alcoholism (with Debra Jay, 3rd ed., Hazelden, 2021), has become a cornerstone in family-centered recovery work, the release said. Over his career, he has led interventions, trained professionals nationally and internationally, and authored articles and books that have influenced modern approaches to treatment and recovery.

“Borden Cottage represents the very best in recovery care—unmatched privacy, impeccable clinical standards, and a holistic approach that honors each individual,” said Jay. “It is an honor to join this team and further the remarkable work already being done here.” 

Jay will focus on leading Borden Cottage’s programs and operations abd strengthen and expand its position as a choice for high‑net‑worth individuals, executives, and public figures seeking discreet, effective treatment, the release said.